Benny the dog

I am a dog. I like treats and cuddles

[grandson @Grandsoncr7]

🚨🗣️Hossam Hassan:

“I can’t get over the match we played against Argentina. I’ve tried rewatching it several times, and I still can’t figure out what the referee and VAR were actually doing.

I’m still trying to understand how Argentina got away without receiving a single yellow card after committing 13 fouls against us, while our Egyptian players were being penalized for lesser fouls.

I think all the teams that have had controversial decisions go in Argentina’s favor should come together and demand a proper review of their matches because this is outright robbery in a World Cup tournament.

They are doing everything to make Messi win the World Cup again, but they don’t realize that even gifting Messi five World Cups won’t place him above Ronaldo, who achieved everything fairly.

FIFA should be ashamed for allowing this to happen in the biggest football tournament in the world.”

[Mark Mitchell @emily1katie]

That’s not to say #AVCT shareholders are not more than entitled to want to see the SP move - BUT - the hot takes from those who didn’t know what a PFS was until last year should probably pipe down. The CEO is 2.5 decades in long oncology trousers. The Chair is 4 decades in long public markets trousers. They know EXACTLY what they are doing.

[TVR5 @TVR5AVCT]

TVR5 will stamp its feet if it believes the company is veering off track for a second.

Our feet are raised.

#AVCT

[Christina Coughlin @coughlin582]

We are thrilled to welcome Patrick to the Board at #AVCT. His deep sector experience building companies and navigating finances, operations and deals on both sides of the Atlantic will be critical for us at this time.

#LetsDoThis
#HopeWithoutCompromise

[Andrew Bridgen @ABridgen]

This is frightening
What are we actually breathing in ?
Heavy metals ?
Please watch this video share and please show it to the unawakened.

[stonks @JStonker]

#AVCT

https://t.co/M0fmwn7k4x

[Sandy Radford @sandyradders]

As has been mentioned before, it was a very upbeat AGM.

During the informal discussions afterwards, Chris answered every question with her customary thoughtfulness and courtesy.

But there are questions… and then there are questions.

One discussion centred on whether FAP expression changes during treatment. Chris became visibly animated because this is a critically important question for the pre|CISION platform.

Previous analysis had already provided important information that has been fundamental to the platform’s development. FAPI-PET takes this a step further by providing a comprehensive, whole-body assessment of FAP expression.

As Chris explained, one limitation of conventional ADCs is that targets such as HER2 are internalised into tumour cells. As treatment continues, HER2 expression can decrease or even be lost. The FAPI-PET data presented so far suggest something very different with FAP. Even as tumours shrink, FAP expression appears to persist.

That is a very important finding. If confirmed in larger datasets, it has the potential to become a game-changing differentiator for the pre|CISION platform and have important implications for AVA6103.

Chris said after the AGM that a lot would become clearer once the BIO data were released. It did.

The inference is that if FAP remains present while tumour cells are being killed, then the activation mechanism for pre|CISION doesn’t disappear as treatment progresses.

Conventional ADCs can run into the issue that the antigen they’re targeting changes over time. If the activating enzyme (FAP) persists instead, there is a scientific rationale that repeated dosing continues to activate drug in the tumour microenvironment.

As Chris said during the BIO presentation:

“The FAPI-PET results are critically important. The fibroblasts aren’t dying. And so the enzyme is still there. So dose 1 versus dose 8, it looks like you’ve got just as much FAP present even though you are killing off the tumour cells. It’s such an important finding for the whole platform, and especially as we’re looking at AVA6103 as it moves into the clinic.”

#AVCT

[Mark Mitchell @emily1katie]

#AVCT AVA7100 being discontinued didn’t get much coverage last week but, to my mind, it was much bigger news than the FDA agreeing no Phase 3 is required for AVA6000 in SGC.

AVA7100 was after all AVCT’s 1st third-generation AffDC.

It comprised a novel FAP-Affimer dimer conjugated to a preCISION PDC of an (undisclosed) payload via standard ADC conjugation techniques.

Simply put, this third-generation technology was intended to enable preCISION to work in low-FAP environments.

However, because AVCT have been able to prove preCISION works in low-FAP environments (via the AVA6000 trial) it does not require the technology in AVA7100 and has thus discontinued it.

Why is this important?

Being able to target low-FAP environments (without requiring additional third-generation technology) means capturing ~90% of the solid tumour market is possible.

Why is Enhertu so celebrated?

Because of its ability to work in low-HER2 environments. I.e. the antigen it requires for activation.

How is preCISION different?

preCISION does not require an antigen. It just requires FAP (now confirmed only low amounts are required for activation).

Enhertu is a blockbuster because of its ability to work in low HER2 environments (not just high HER2, which is a tiny % of the market).

Discontinuation of AVA7100 is the green light that preCISION can work across ~90% of the solid tumours market (from high FAP to low FAP).

The financial implications of this finding are huge. Bigger than AVA6103, AVA6000 & AVA6207 combined.

Why? It proves the platform’s enormously wide utility.

AVA6103 13 weeks into trial tomorrow. Equity has some real momentum again.

Really good to see for shareholders who have kept the faith for half a decade plus.

Here we go again #AVCT

[Christopher Leidli @chrisleidli]

What if chemotherapy could target only the tumor, sparing healthy tissues from harm?

Christina Coughlin, MD, PhD, unveils a revolutionary approach that transforms this dream into reality.

Imagine concentrating treatment in the tumor with up to 100 times the potency found in the bloodstream, enhancing care and hope for patients everywhere.

🎧 Learn how precision therapies are redefining the future of cancer care in the latest podcast episode of Rx for Biotech, now available on YouTube and all major streaming platforms. platforms.

#podcast #cancer #chemotherapy

[Rupert Lowe MP @RupertLowe10]

It has now reached the point where I truly believe that public officials and politicians who continue to knowingly import third world savages into our communities should be prosecuted.

It is that reckless, that irresponsible, that dangerous.

People need to go to prison.

[Rupert Lowe MP @RupertLowe10]

I am utterly horrified at the idea of Labour importing thousands and thousands more refugees - Sudan? Afghanistan? Somalia?

It is evil.

I am calling on both Reform and the Tories to match Restore Britain's commitment to deport anyone who arrives through this scheme.

We must make it abundantly clear that ANYONE who arrives on these routes will NOT stay.

That is the only way we can stop this now.

2029 is too late.

We need to end it NOW.

[TVR5 @TVR5AVCT]

Very few prospective shareholders and/or commentators ever mention #AVCT’s core USP: no need for an antibody.

The antibody is a large, expensive component of the Antibody Drug Conjugate (ADC).

Doing away with the need for it is a revolutionary change in drug delivery.

[RAH @RAH00084]

#AVCT

Trial design (and costs) must be locked down before quantum can be agreed. Now resolved. No confirmatory (and expensive) Phase 3 required for AVA6000 in SGC.

AVA7100 terminated due to how good AVA6000 has proven in the low FAP environment.

No additional FAP testing required (pre trial) owing to this finding.

Critical for platform. Consider the additional implications for AVA6103 and beyond.

Remarkably the PFS in SGC has still not be found. Language around TNBC (‘still maturing’) suggests it too has not yet been found. Remarkable.

Data pre-FDA lifting dosing limit and post an important data point for those looking to partner AVA6000. Interesting but unsurprising to hear that flagged.

FDA validation enveloping preCISION from every angle.

Deputy chair to be independent in keeping with US listing trends.

Heights now representing <3.5% market cap.

Over 12% of TVR turning out for what was a procedural and irrelevant AGM means no 90%+ squeeze out takeover via the back door will be happening.

AVA6103 over 4 months into trial. Serious cumulative doses of EXd will now have been administered. BOIN structure remains unappreciated.

An historically cautious CEO now talking to ‘platform validation’. If you think she is talking platform validation on the basis of AVA6000 findings alone, I’ve a lovely bridge to sell you.

It works. Both of them.

[TVR5 @TVR5AVCT]

It is clear the relationship @coughlin582 has built with the FDA since her appointment as CEO of #AVCT will serve shareholders very well. Not just for AVA6000 but for AVA6103 and beyond.

A biotech on the cusp of deal(s) and - inevitably - a takeover.

Well done team @avacta.

[Avacta @avacta]

BIO International 2026: Faridoxorobicin update with Avacta CEO @coughlin582. https://t.co/K1F7yECegv #AVCT

[Avacta @avacta]

Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference. https://t.co/9WALVjnRlB #AVCT

[Rupert Lowe MP @RupertLowe10]

Restore Britain has released detailed policy papers on mass deportations, abolishing inheritance tax, restoring the British pub, strengthening self-defence laws and our incredible plan to make energy cheap and reliable.

Separately to that, the rape gang inquiry report with its many recommendations.

More papers are to come soon - on the immigration red list, policing, economics, national security and plenty of others.

We are outlining our blueprint on how to Restore Britain.

Hundreds of pages.

It takes time and effort to put this together, and I want to thank our policy team for their work.

But we are producing the most detailed policy papers released by any political party.

We are doing our homework.

[Basil the Great @BasilTheGreat]

It's time polling companies started prompting for Restore Britain

If you agree share and comment so they're bombarded with notifications

We demand to be represented fairly

@YouGov
@Moreincommon_
@FindoutnowUK
@DeltapollUK
@Survation
@OpiniumResearch

[Secretary Kennedy @SecKennedy]

Thank you, Tulsi, for documenting Dr. Fauci's central role in causing the COVID-19 pandemic — among the most consequential crimes in human history.

[DNI Tulsi Gabbard @DNIGabbard]

Today, on my final day as Director of National Intelligence, I’m releasing never-before-seen communications and documents exposing how Dr. Fauci provided millions in US taxpayer dollars to fund dangerous gain-of-function research at the Wuhan lab, worked with politicized elements within the Intelligence Community to suppress the truth about his actions and hide the virus’ lab-leak origins, and lied to Congress while under oath in 2024. It’s time you know the truth.

https://t.co/3YJSstB7d4